Cytokinetics' (CYTK) omecamtiv Approval Highly Likely, Data Are Encouraging and Suggest Useful Benefit, Reiterate Buy - H. C. Wainwright

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Cytokinetics' (CYTK) omecamtiv Approval Highly Likely, Data Are Encouraging and Suggest Useful Benefit, Reiterate Buy - H. C. Wainwright

Cytokinetics (CYTK) Announces FDA Acceptance of NDA for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction

February 4, 2022 7:30 AM EST

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted and filed the companys New Drug Application (NDA) for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction (HFrEF).

The FDA assigned the NDA a standard review with a Prescription Drug User... More